Merck & Co. Research Coverage Started at Deutsche Bank (MRK)
Analysts at Deutsche Bank started coverage on shares of Merck & Co. (NYSE:MRK) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “hold” rating and a $63.00 price target on the stock. Deutsche Bank’s target price points to a potential upside of 4.65% from the company’s current price. The analysts noted that the move was a valuation call.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Monday, August 18th. They now have a $62.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Merck & Co. from $63.00 to $60.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Merck & Co. in a research note on Thursday, July 31st. They now have a $59.00 price target on the stock, up previously from $56.00. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Merck & Co. has an average rating of “Hold” and a consensus price target of $60.80.
Shares of Merck & Co. (NYSE:MRK) traded up 0.29% during mid-day trading on Wednesday, hitting $60.375. 2,845,542 shares of the company’s stock traded hands. Merck & Co. has a 52 week low of $44.62 and a 52 week high of $60.40. The stock’s 50-day moving average is $58.01 and its 200-day moving average is $57.12. The company has a market cap of $174.2 billion and a P/E ratio of 31.72. Merck & Co. also saw unusually large options trading on Monday. Stock traders acquired 5,003 put options on the company. This is an increase of approximately 111% compared to the average daily volume of 2,366 put options.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.05. The company had revenue of $10.93 billion for the quarter, compared to the consensus estimate of $10.60 billion. During the same quarter in the prior year, the company posted $0.84 earnings per share. The company’s quarterly revenue was down .7% on a year-over-year basis. On average, analysts predict that Merck & Co. will post $3.49 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 2.92%. The ex-dividend date is Thursday, September 11th.
In other Merck & Co. news, EVP Adam H. Schechter unloaded 22,000 shares of Merck & Co. stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $59.70, for a total transaction of $1,313,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Merck & Co, Inc (NYSE:MRK), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Receive News & Ratings for Merck & Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.